In this short clip from our BIO 2025 interview with him, Tevard Biosciences CEO Daniel Fischer explains tRNA-based suppression of premature stop codons—mutations that account for about 25% of Dravet cases and up to 20% of other genetic diseases. This suppressor tRNA platform is disease-agnostic, allowing for the same construct to potentially treat multiple conditions, including Duchenne muscular dystrophy and dilated cardiomyopathy.

Access our full interview with Fischer here!

Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Subscribe Now!

How tRNAs Could Revolutionize Treatment for Dravet & More

Newsletter